World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
71
Citations
34255
World Ranking
2266
National Ranking
1097

Julie E. Ledgerwood publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Julie E. Ledgerwood sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 160 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Julie E. Ledgerwood D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Julie E. Ledgerwood sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 71 D-Index — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Julie E. Ledgerwood is affiliated with the National Institute of Allergy and Infectious Diseases in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a particular focus on infectious diseases, virology, epidemiology, immunology, and public health.

Their main topics of study include:

  • HIV Research and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • Viral Infections and Outbreaks Research
  • Animal Virus Infections Studies
  • Mosquito-borne diseases and control
  • Monoclonal and Polyclonal Antibodies Research

Ledgerwood has contributed significantly to various scientific publications. Frequent venues for their work are:

  • New England Journal of Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • The Lancet Infectious Diseases
  • Science

Some recent papers include:

  • "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report," 2020, New England Journal of Medicine
  • "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults," 2020, New England Journal of Medicine
  • "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates," 2020, New England Journal of Medicine
  • "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination," 2020, New England Journal of Medicine
  • "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19," 2021, New England Journal of Medicine

Frequent co-authors collaborating with Ledgerwood include:

  • John R. Mascola
  • Adrian B. McDermott
  • Barney S. Graham
  • Emily E. Coates
  • Martin R. Gaudinski

Best Publications

  • Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

    Lindsey R. Baden;Hana M El Sahly;Brandon J Essink;Karen Kotloff

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

  • A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

    Mulangu S;Dodd Le;Davey Rt;Tshiani Mbaya O

  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

    Evan J. Anderson;Nadine G. Rouphael;Alicia T. Widge;Lisa A. Jackson

  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

    Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica

  • Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

    Robert A. Seder;Lee Jah Chang;Mary E. Enama;Kathryn L. Zephir

  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

    Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson

  • Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

    Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell

  • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.

    Hana M El Sahly;Lindsey R Baden;Brandon Essink;Susanne Doblecki-Lewis

  • Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.

    Pegu, Amarendra, O’Connell, Sarah E.;Stephen D. Schmidt;O’Dell, Sijy, Talana, Chloe A.

  • Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

    Katharine J Bar;Michael C Sneller;Linda J Harrison;J Shawn Justement

  • Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

    Rebecca M. Lynch;Eli Boritz;Emily E. Coates;Adam DeZure

  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

    Lawrence Corey;Peter B Gilbert;Michal Juraska;David C Montefiori

  • A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

    Jason A. Regules;John H. Beigel;Kristopher M. Paolino;Jocelyn Voell

  • Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

    Joan O. Ngwuta;Man Chen;Kayvon Modjarrad;Kayvon Modjarrad;M. Gordon Joyce

  • Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

    Davide Corti;John Misasi;Sabue Mulangu;Daphne A. Stanley

  • Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

    Andrew S Ishizuka;Kirsten E Lyke;Adam DeZure;Andrea A Berry

  • Chimpanzee Adenovirus Vector Ebola Vaccine

    Julie E. Ledgerwood;Adam D. DeZure;Daphne A. Stanley;Emily E. Coates

  • Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

    M. Gordon Joyce;Adam K. Wheatley;Paul V. Thomas;Gwo-Yu Chuang

  • A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

    Katie Ewer;Tommy Rampling;Navin Venkatraman;Georgina Bowyer

  • Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

    Rebecca S. Rudicell;Young Do Kwon;Sung-Youl Ko;Amarendra Pegu

Frequent Co-Authors

Barney S. Graham
Barney S. Graham Morehouse School of Medicine
John R. Mascola
John R. Mascola ModeX Therapeutics
Robert T. Bailer
Robert T. Bailer National Institute of Allergy and Infectious Diseases
Richard A. Koup
Richard A. Koup National Institute of Allergy and Infectious Diseases
Adrian B. McDermott
Adrian B. McDermott National Institute of Allergy and Infectious Diseases
Mario Roederer
Mario Roederer National Institute of Allergy and Infectious Diseases
Martha C. Nason
Martha C. Nason National Institutes of Health
Gary J. Nabel
Gary J. Nabel ModeX Therapeutics
Theodore C. Pierson
Theodore C. Pierson National Institute of Allergy and Infectious Diseases
Nancy J. Sullivan
Nancy J. Sullivan National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in immunology, pursuing related nursing degrees online can open diverse career pathways in healthcare. Many aspiring nurses start with foundational programs like the easiest accelerated nursing programs to get into, allowing them to fast-track their education and begin clinical work sooner.

For non-nurses seeking to enter the nursing field, online options such as online RN programs for non nurses in Florida provide flexibility and accessibility. These programs cater to career changers and help build essential clinical expertise, which complements immunology knowledge in patient care settings.

Those who have already earned a Family Nurse Practitioner (FNP) credential can enhance their scope by enrolling in an fnp to acute care np bridge program. This pathway is ideal for professionals aiming to specialize in acute care environments, where immunological knowledge is critical for managing complex cases.

Additionally, accelerated FNP programs offer a streamlined route for nurses looking to advance their careers and integrate immunology principles into advanced practice roles. These programs combine rigorous clinical training with cutting-edge research, preparing graduates for impactful careers in immunology-related health fields.

Best Scientists Citing Julie E. Ledgerwood

Trending Scientists